Archiv
Archiv anzeigen:
bis


Report from the 60th American Society of Hematology Annual Meeting

David Green, MD, PhD

Highlights of the latest research


The 2018 San Antonio Breast Cancer Symposium

William J. Gradishar, MD

Highlights of the latest research


Genetic Testing for Breast Cancer: How Effective Are Guidelines?

Henry Mark Kuerer, MD, PhD, FACS reviewing Beitsch PD et al. J Clin Oncol 2018 Dec 7, Milliron KJ and Griggs JJ. J Clin Oncol 2018 Dec 7

National Comprehensive Cancer Network guidelines for multigene panel testing miss nearly half of patients with actionable variants.


NEJM Journal Watch Oncology and Hematology Top Stories of 2018

William J. Gradishar, MD

A perspective on the most important research in the field from the past year


Trifluridine/Tipiracil for Advanced Chemotherapy-Refractory Gastric Cancer

David H. Ilson, MD, PhD reviewing Shitara K et al. Lancet Oncol 2018 Nov 1

Overall survival was significantly longer with trifluridine/tipiracil than with placebo.


Ibrutinib as Initial Therapy for Chronic Lymphocytic Leukemia

Michael E. Williams, MD, ScM reviewing Woyach JA et al. N Engl J Med 2018 Dec 1

Older patients with previously untreated disease had better outcomes with ibrutinib than with chemo-immunotherapy.


A New Complement Inhibitor for Paroxysmal Nocturnal Hemoglobinuria

David Green, MD, PhD reviewing Lee JW et al. Blood 2018 Dec 3, Kulasekararaj AG et al. Blood 2018 Dec 3

Ravulizumab was noninferior to eculizumab in both previously treated and treatment-naive patients.


CAR-T Cell Therapy for Diffuse Large B-Cell Lymphoma

Michael E. Williams, MD, ScM reviewing Schuster SJ et al. N Engl J Med 2018 Dec 1

Forty percent of patients with relapsed or refractory disease achieved complete remission.


Utility of Radical Prostatectomy for Localized Prostate Cancer

Robert Dreicer, MD, MS, MACP, FASCO reviewing Bill-Axelson A et al. N Engl J Med 2018 Dec 13

At 23 years of follow-up, life expectancy was nearly 3 years longer with prostatectomy than with watchful waiting.


Thromboprophylaxis with Apixaban for Cancer Patients

David Green, MD, PhD reviewing Carrier M et al. N Engl J Med 2018 Dec 4

Venous thromboembolism occurred less frequently with the direct oral anticoagulant apixaban than with placebo.


Archiv
Seite von 77
Editorial Member Board Empfehlungen

Prof. Dr. med. Christoph Rochlitz

Chefarzt Onkologie
Universitätsspital Basel

E-Mail: E-Mail anzeigen

Liebe Kolleginnen und Kollegen!

In der vorliegenden Ausgabe von NEJM Journal Watch möchte ich Ihnen gerne wieder einige rezent publizierte Studien aus dem Bereich Onkologie/Hämatologie näherbringen.

Kommentar weiterlesen

First-Line Atezolizumab for Metastatic Nonsquamous NSCLC

Anne S. Tsao, MD reviewing Socinski MA et al. N Engl J Med 2018 Jun 14

Adding atezolizumab to bevacizumab and chemotherapy improved survival in chemotherapy-naive patients with non–small-cell lung cancer, regardless of EGFR or ALK mutation status.


Cytoreductive Nephrectomy for Metastatic Kidney Cancer

Robert Dreicer, MD, MS, FACP, FASCO reviewing Méjean A et al. N Engl J Med 2018 Jun 3, Motzer RJ and Russo P. N Engl J Med 2018 Jun 3

Adding nephrectomy to standard sunitinib therapy did not improve survival in patients with poor- and intermediate-risk disease.


ASCO 2018 Report — Breast Cancer

William J. Gradishar, MD

Highlights of the latest treatments


Intensive Surveillance for Colorectal Cancer

David H. Ilson, MD, PhD reviewing Wille-Jørgensen P et al. JAMA 2018 May 22, Sanoff HK. JAMA 2018 May 22

More- versus less-frequent testing did not improve survival after curative treatment for patients with stage II–III disease.


Fewer Patients with Breast Cancer Require Chemotherapy

William J. Gradishar, MD reviewing Sparano JA et al. N Engl J Med 2018 Jun 3

Outcomes were noninferior with endocrine therapy alone versus chemo-endocrine therapy in patients with intermediate recurrence scores.


Chemotherapy for Isolated Locoregional Recurrence of Breast Cancer

Henry Mark Kuerer, MD, PhD, FACS reviewing Wapnir IL et al. J Clin Oncol 2018 Apr 10

Long-term results confirm a benefit for ER-negative but not ER-positive patients.


Neoadjuvant Nivolumab for Resectable Lung Cancer

Anne S. Tsao, MD reviewing Forde PM et al. N Engl J Med 2018 Apr 16

A major pathological response was seen in 45% of patients.


First-Line Nivolumab plus Ipilimumab for Advanced Non–Small-Cell Lung Cancer

Anne S. Tsao, MD reviewing Hellmann MD et al. N Engl J Med 2018 Apr 16

Progression-free survival was improved versus chemotherapy for patients with high tumor mutation burden.


First-Line Lenvatinib vs. Sorafenib for Unresectable Hepatocellular Carcinoma

David H. Ilson, MD, PhD reviewing Kudo M et al. Lancet 2018 Feb 9, Reig M and Bruix J. Lancet 2018 Feb 9

Overall survival was noninferior and progression-free survival and response were superior with lenvatinib.


Apalutamide for Castration-Resistant PSA-Only Prostate Cancer

Robert Dreicer, MD, MS, FACP, FASCO reviewing Smith MR et al. N Engl J Med 2018 Feb 8

Metastasis-free survival was significantly longer with apalutamide than with placebo.